glp-1 cardiovascular outcomes trial results august 2025 The Big of a drug (Wegovy) to Reduce Major Events GLP-1 Agonists in Cardiovascular Diseases:
Description
That growth is driven almost entirely by the success of prescription GLP-1 drugs and the desire of consumers to access similar benefits without injections, prescriptions, or high costs
doi: 10.2165/11592810-000000000-00000 138 SandersDM
But, as with any drug, GLP-1s should be used under the close supervision of a health care professional and sourced from state-licensed pharmacies
Both healthcare professionals and patients can submit reports, contributing to ongoing medication safety monitoring across the UK
March 2024
Zinc: protecting immune function and metabolism Research on GLP-1 users found significant decreases in serum zinc levels alongside weight reduction
